Latest news with #SanofiIndia
&w=3840&q=100)
Business Standard
21-05-2025
- Health
- Business Standard
Bharat Biotech's oral cholera vaccine Hillchol clears phase 3 trials
Bharat Biotech, the makers of Covaxin, on Tuesday said that their oral cholera vaccine Hillchol has demonstrated against both the Ogawa and Inaba serotypes of Cholera in both adults and children in a phase 3 clinical study across 1800 individuals. Cholera is an acute diarrhoeal infection caused by ingesting food or water contaminated with Vibrio cholerae bacteria. Studies have estimated that 2.86 million cases and 95,000 deaths occur annually. "Global demand for OCVs is close to 100 million doses a year, and given that only one manufacturer supplies them, there is a global shortage. Bharat Biotech's facilities in Hyderabad and Bhubaneswar have a capacity to produce up to 200 million doses of Hillchol," the company said. Sanofi India makes an oral cholera vaccine The double-blind, randomised phase 3 clinical trial was evaluating safety, immunogenicity and non-inferiority as well as a lot-to-lot consistency of single component oral cholera vaccine Hillchol in comparison to a comparator vaccine in an 1800 participant study across 10 clinical sites in India. In this study, participants were divided into three age groups: adults over 18 years, children aged 5 to under 18 years, and infants aged 1 to under 5 years. They were randomized in a 3:1 ratio to receive either Hillchol or a comparator above study findings have been published in the ScienceDirect, Vaccine journal. The primary endpoint focused on the proportion of participants achieving over 4-fold increase in vibriocidal antibody titres against Ogawa and Inaba serotypes 14 days after two doses. Bharat Biotech claimed that Hillchol demonstrated 4-fold rise in vibriocidal antibodies against both Ogawa (68.3 per cent) and Inaba (69.5 per cent) serotypes, proving non-inferiority to licensed vaccines. It also demonstrated a strong safety profile and was well-tolerated across all age groups including infants less than 1 year old. "This publication reaffirms our commitment to advancing vaccines built on rigorous research, thorough clinical trials, and reliable clinical data. It highlights our continued commitment to providing affordable, effective, and accessible vaccines for the populations who need them the most,' said Krishna Ella, Executive Chairman of Bharat Biotech. Dr. Ella added, 'Cholera is a vaccine-preventable disease that has faced a surge in outbreaks along with a huge shortage of vaccines. The new generation Oral Cholera Vaccine Hillchol, featuring a simplified single stable O1 Hikojima strain, inducing robust antibodies against both Ogawa and Inaba serotypes, aims to enhance production efficiency and affordability, particularly in lower- and middle-income countries where waterborne diseases continue to pose serious health threats.'
Business Standard
15-05-2025
- Business
- Business Standard
Sanofi India consolidated net profit declines 12.52% in the March 2025 quarter
Sales rise 4.91% to Rs 535.90 croreNet profit of Sanofi India declined 12.52% to Rs 119.50 crore in the quarter ended March 2025 as against Rs 136.60 crore during the previous quarter ended March 2024. Sales rose 4.91% to Rs 535.90 crore in the quarter ended March 2025 as against Rs 510.80 crore during the previous quarter ended March EndedMar. 2025Mar. 2024% 5 OPM %32.0826.84 -PBDT174.90140.30 25 PBT165.30131.20 26 NP119.50136.60 -13 Powered by Capital Market - Live News
&w=3840&q=100)
Business Standard
14-05-2025
- Business
- Business Standard
Sanofi India Q4 results: Profit falls 12.5% to ₹119.5 cr, revenue up 4.9%
Sanofi India on Wednesday announced a 12.5 per cent year-on-year (Y-o-Y) decline in consolidated net profit for the March quarter (Q4 FY25) to ₹119.5 crore, down from ₹136.6 crore reported for the same period last year. The company's revenue from operations rose 4.91 per cent Y-o-Y to ₹535.9 crore, compared to ₹510.8 crore in Q4 FY24. 'The successful launch of Soliqua, our best-in-class diabetes drug for the premix segment, continues with steady growth, reinstating confidence and strength in our comprehensive diabetes portfolio,' the company said. Sanofi India was able to increase its operating profit in the March quarter by 27 per cent compared to the same period last year. The improvement was attributed to the company's continued focus on lowering expenses through overall operating efficiencies. Commenting on the results, Rachid Ayari, wholetime director and chief financial officer (CFO) at Sanofi India, said: 'Sanofi will continue to focus on driving further improvement in operating efficiencies while expanding the availability of its best-in-class innovative products in India.' On Wednesday, Sanofi India's shares rose 1.92 per cent to ₹6,042.35 apiece on the Bombay Stock Exchange (BSE). The results were released after market hours.
Business Standard
03-05-2025
- Business
- Business Standard
Sanofi Consumer reports 20% YoY fall in Q1 PAT to Rs 50 cr
Sanofi Consumer Healthcare India (SCHIL) reported a 20.25% year-on-year (YoY) decline in net profit to Rs 50 crore for the quarter ended 31 March 2025, compared to Rs 62.70 crore in the same period last year. Revenue from operations fell 22.11% YoY to Rs 172.60 crore in the quarter ended 31 March 2025. On a sequential basis, net profit rose 12.86% and revenue increased 1.11% compared to Q4 2024. During the quarter, total expenses declined 12.10% YoY to Rs 111 crore, primarily due to a 71.70% reduction in the cost of materials consumed and a 29.34% decline in other expenses. Profit before tax slipped 20.38% to Rs 66.80 crore in the first quarter of 2025, compared to Rs 83.90 crore reported in the same period last year. The quarter also saw the successful launch of Allegra D, a new addition to the existing portfolio of Allegra variants in India a brand with over 25 years of legacy in the country. The company noted that Q1 2025 and Q1 2024 are not directly comparable due to the demerger and a voluntary product recall of certain key brand variants. Himanshu Bakshi, managing director, Sanofi Consumer Healthcare India, said, We continue to focus on strengthening our operations and continue to bring superior, simple and accessible products that enable consumers to control their own health. Our commitment to delivering high-quality, science-backed products remains at the core of our integrated growth strategy. SCHIL emerged as a distinct legal entity following its demerger from Sanofi India, executed under a Scheme of Arrangement approved by the Mumbai Bench of the National Company Law Tribunal, which became effective on 1 June 2024. This demerger aligns with Sanofi's global strategy, allowing SCHIL to operate independently with a focused mandate in the consumer healthcare sector. Sanofi Consumer Healthcare India is a leading player in India's consumer healthcare market. Leveraging Sanofis global experience, SCHIL aims to improve consumer well-being through a portfolio spanning allergy, digestive wellness, pain care, multivitamins, and herbal/traditional dietary supplements. Its key brands include Allegra, DePURA, Avil, and Combiflam. The scrip shed 0.08% to end at Rs 4,938.45 on the BSE on Friday.
Mint
25-04-2025
- Business
- Mint
Muthoot Finance, Sanofi India to trade ex-dividend today; Ami Organics to trade ex-split today
Dividend Stocks: Muthoot Finance, Sanofi India share prices will remain in focus on Friday as will trade ex-dividend today. In addition Ami Organics shares will also remain in focus as will trade ex-split today. The record date for dividend and stock split of these companies had been fixed on Friday 25 April 2025 to identify the list of eligible shareholders to benefit Record date implies that the investors who wanted to benefit and receive dividend payout of Stocks after split needed to buy shares of these companies as Muthoot Finance, Sanofi India, Ami Organics a day prior to the record date for their names to appear in the list of eligible share holders to receive the dividend or stocks after split, as per the T+1 Settlement procedure Sanofi India- The Board of Directors at its meeting held on 27th February 2025, had recommended a final dividend of ₹ 117/- per equity share of the face value of ₹ 10 each for the Financial Year ended 31st December 2024, which was subject to the approval of Shareholders at the ensuing 69th Annual General Meeting. In the above context, Sanofi India also had announced that the payment of the Final Dividend will be made to those members whose names are on the Company's Register of Members on Friday, 25th April 2025 which stands as the Record Date for identifying the Beneficial Owners Muthoot Finance- The Board Meeting held on April 21, 2025, had Considered and approved the payment of an interim dividend of Rs. 26 (Rupees Twenty Six) per equity share (260%) for the Financial Year 2024-25. Muthoot finance already had announced Friday 25 April 2025 to be the record date for identifying eligible shareholders to receive dividend Ami Organics had fixed Friday, April 25, 2025 as the 'Record Date' for determining entitlement of equity shareholders for the purpose of for split/ sub-division of existing equity shares of the Company, such that 1 (one) equity share having face value of Rs. 10/- (Rupees ten only) each, fully paid-up, will be sub-divided into 2 (Two) equity shares having face value of Rs. 5/- (Rupees Five only) each, fully paid up Disclaimer: The views and recommendations given in this article are those of individual analysts. These do not represent the views of Mint. We advise investors to check with certified experts before making any investment decisions. First Published: 25 Apr 2025, 09:01 AM IST
